161 related articles for article (PubMed ID: 21456384)
1. Anthracyclines are a critical component of adjuvant chemotherapy regimens for high-risk early breast cancer.
Morris PG; Hudis CA; Dang CT
Oncology (Williston Park); 2011 Feb; 25(2):134-5, 138, 140. PubMed ID: 21456384
[No Abstract] [Full Text] [Related]
2. Seeing red: anthracyclines for breast cancer.
Andreopoulou E; Sparano JA
Oncology (Williston Park); 2011 Feb; 25(2):128, 131, 134. PubMed ID: 21456383
[No Abstract] [Full Text] [Related]
3. Anthracyclines in early-stage breast cancer: is it the end of an era?
Robson D; Verma S
Oncologist; 2009 Oct; 14(10):950-8. PubMed ID: 19561291
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant anthracyclines: time for a change of heart?
O'Regan R
Oncology (Williston Park); 2011 Feb; 25(2):140, 142. PubMed ID: 21456385
[No Abstract] [Full Text] [Related]
6. Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
Oakman C; Moretti E; Sotiriou C; Viale G; Di Leo A
J Natl Cancer Inst; 2009 Dec; 101(24):1735-6; author reply 1736-7. PubMed ID: 19893008
[No Abstract] [Full Text] [Related]
7. Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
Nielsen KV; Brünner N
J Natl Cancer Inst; 2011 Feb; 103(4):352-3. PubMed ID: 21217082
[No Abstract] [Full Text] [Related]
8. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Erber R; Gluz O; Brünner N; Kreipe HH; Pelz E; Kates R; Bartels A; Huober J; Mohrmann S; Moustafa Z; Liedtke C; Möbus V; Augustin D; Thomssen C; Jänicke F; Kiechle M; Kuhn W; Nitz U; Harbeck N; Hartmann A
Breast Cancer Res Treat; 2015 Apr; 150(2):279-88. PubMed ID: 25721604
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline war: no victor yet.
Young P
J Natl Cancer Inst; 2009 Sep; 101(17):1171-3. PubMed ID: 19706625
[No Abstract] [Full Text] [Related]
10. Adjuvant chemotherapy for the treatment of HER2-positive early breast cancer.
Clavarezza M; Venturini M
Oncology; 2009; 77 Suppl 1():14-7. PubMed ID: 20130427
[TBL] [Abstract][Full Text] [Related]
11. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
Biesaga B; Niemiec J; Ziobro M; Wysocka J; Kruczak A
Breast; 2011 Aug; 20(4):338-50. PubMed ID: 21507646
[TBL] [Abstract][Full Text] [Related]
12. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
Pritchard KI
Oncologist; 2009 Oct; 14(10):959-62. PubMed ID: 19819915
[No Abstract] [Full Text] [Related]
13. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer.
Buzdar AU
J Clin Oncol; 2006 Jun; 24(16):2409-11. PubMed ID: 16682721
[No Abstract] [Full Text] [Related]
14. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
Hertel PB; Tu D; Ejlertsen B; Jensen MB; Balslev E; Jiang S; O'Malley FP; Pritchard KI; Shepherd LE; Bartels A; Brünner N; Nielsen TO
Breast Cancer Res Treat; 2012 Feb; 132(1):225-34. PubMed ID: 22160637
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
Jasra S; Anampa J
Curr Treat Options Oncol; 2018 May; 19(6):30. PubMed ID: 29752560
[TBL] [Abstract][Full Text] [Related]
16. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?
Pritchard KI
J Clin Oncol; 2009 Aug; 27(24):3875-6. PubMed ID: 19620479
[No Abstract] [Full Text] [Related]
17. Chemotherapy regimens in early breast cancer: major controversies and future outlook.
Joerger M; Thürlimann B
Expert Rev Anticancer Ther; 2013 Feb; 13(2):165-78. PubMed ID: 23406558
[TBL] [Abstract][Full Text] [Related]
18. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.
Ejlertsen B; Jensen MB; Nielsen KV; Balslev E; Rasmussen BB; Willemoe GL; Hertel PB; Knoop AS; Mouridsen HT; Brünner N
J Clin Oncol; 2010 Feb; 28(6):984-90. PubMed ID: 20038724
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the use of anthracyclines in older patients with breast cancer.
Morris PG; Fornier MN
Crit Rev Oncol Hematol; 2011 Feb; 77(2):131-41. PubMed ID: 20227291
[TBL] [Abstract][Full Text] [Related]
20. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]